Log in
NASDAQ:ABMD

Abiomed Competitors

$266.43
-1.78 (-0.66 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$265.35
Now: $266.43
$271.68
50-Day Range
$251.88
MA: $272.41
$290.51
52-Week Range
$119.01
Now: $266.43
$319.19
Volume221,065 shs
Average Volume546,438 shs
Market Capitalization$12.04 billion
P/E Ratio58.56
Dividend YieldN/A
Beta1.42

Competitors

Abiomed (NASDAQ:ABMD) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ABMD stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Abiomed, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abiomed (NASDAQ:ABMD) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Abbott Laboratories10.50%18.19%8.29%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Abbott Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Abbott Laboratories141302.67

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than Abiomed. Abbott Laboratories is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Abiomed beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Medtronic15.80%10.47%5.80%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Medtronic132012.84

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Medtronic has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than Abiomed. Medtronic is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Abiomed beats Medtronic on 9 of the 15 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Stryker11.38%20.53%8.89%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Stryker291512.56

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Stryker has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Given Stryker's stronger consensus rating and higher possible upside, analysts clearly believe Stryker is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Stryker's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Stryker$14.88 billion5.88$2.08 billion$8.2628.21

Stryker has higher revenue and earnings than Abiomed. Stryker is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Abiomed on 9 of the 15 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Intuitive Surgical24.45%12.08%10.44%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Intuitive Surgical371202.41

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Intuitive Surgical has a consensus target price of $718.2778, suggesting a potential downside of 0.11%. Given Intuitive Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Intuitive Surgical is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than Abiomed. Abiomed is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Abiomed on 9 of the 14 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Becton, Dickinson and5.11%13.30%5.60%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Becton, Dickinson and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Becton, Dickinson and07712.60

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Abiomed. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Abiomed on 8 of the 15 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

86.0% of Abiomed shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abiomed and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Edwards Lifesciences18.18%29.00%18.10%

Analyst Recommendations

This is a summary of current ratings for Abiomed and Edwards Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12302.33
Edwards Lifesciences251302.55

Abiomed presently has a consensus target price of $223.00, suggesting a potential downside of 16.30%. Edwards Lifesciences has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Abiomed.

Volatility and Risk

Abiomed has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares Abiomed and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million14.32$203.01 million$4.7456.21
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Abiomed. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Abiomed on 8 of the 14 factors compared between the two stocks.


Abiomed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27-1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97-0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01-0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05-1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48-1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70-0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33-1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79-1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77-1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09-1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57-0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89-0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07-1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14-0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09-3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50-0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50-1.0%$13.52 billion$937.84 million63.77
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55-0.1%$6.52 billion$2.91 billion31.47
Globus Medical logo
GMED
Globus Medical
1.5$58.47-1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78-0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98-0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32-2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18-2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37-2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24-1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90-1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55-2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87-4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14-2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12-2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52-0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40-11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98-1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94-1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.